Thomas Weisel keeps the outperform rating on Santarus (SNTS).
Analyst Donald Ellis says Santarus expects to launch its new Rapinex product in the fourth quarter, ahead of his first-half 2005 estimate. He notes the 230-member salesforce will detail Rapinex to high-prescribing physicians in treating gastrointestinal disorders. He expects FDA approval of 40 mg Rapinex powder-for-suspension by year end.
Ellis says the company's immediate-release, proton pump inhibitor technology provides a more rapid onset of action than the ones currently on the market. He maintains the 48 cents second-quarter loss, and the $2.48 2004 loss estimates until he has a better grasp on launch quantities.